Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Laboratory for Metabolism and Vascular Medicine, Division of General Internal Medicine, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Am J Clin Nutr. 2021 Feb 2;113(2):391-400. doi: 10.1093/ajcn/nqaa332.
There is an ongoing debate on whether fructose plays a role in the development of nonalcoholic fatty liver disease.
The aim of this study was to investigate the effects of fructose restriction on intrahepatic lipid (IHL) content in a double-blind randomized controlled trial using an isocaloric comparator.
Between March 2017 and October 2019, 44 adult overweight individuals with a fatty liver index ≥ 60 consumed a 6-wk fructose-restricted diet (<7.5 g/meal and <10 g/d) and were randomly assigned to supplementation with sachets of glucose (= intervention group) or fructose (= control group) 3 times daily. Participants and assessors were blinded to the allocation. IHL content, assessed by proton magnetic resonance spectroscopy, was the primary outcome and glucose tolerance and serum lipids were the secondary outcomes. All measurements were conducted in Maastricht University Medical Center.
Thirty-seven participants completed the study protocol. After 6 wk of fructose restriction, dietary fructose intake and urinary fructose excretion were significantly lower in the intervention group (difference: -57.0 g/d; 95% CI: -77.9, -39.5 g/d; and -38.8 μmol/d; 95% CI: -91.2, -10.7 μmol/d, respectively). Although IHL content decreased in both the intervention and control groups (P < 0.001 and P = 0.003, respectively), the change in IHL content was more pronounced in the intervention group (difference: -0.7% point, 95% CI: -2.0, -0.03% point). The changes in glucose tolerance and serum lipids were not significantly different between groups.
Six weeks of fructose restriction per se led to a small, but statistically significant, decrease in IHL content in comparison with an isocaloric control group.This trial was registered at clinicaltrials.gov as NCT03067428.
果糖是否在非酒精性脂肪性肝病的发生发展中起作用仍存在争议。
本研究旨在通过一项采用等热量对照剂的双盲随机对照试验,研究果糖限制对肝内脂质(IHL)含量的影响。
2017 年 3 月至 2019 年 10 月,44 名超重成年人(脂肪肝指数≥60)摄入 6 周的果糖限制饮食(每餐<7.5 g,每天<10 g),并随机分为 3 次/天补充葡萄糖(=干预组)或果糖(=对照组)。参与者和评估者对分组均不知情。质子磁共振波谱法评估的 IHL 含量是主要结局,葡萄糖耐量和血清脂质是次要结局。所有测量均在马斯特里赫特大学医学中心进行。
37 名参与者完成了研究方案。在果糖限制 6 周后,干预组的饮食果糖摄入量和尿果糖排泄量显著降低(差值:-57.0 g/d;95%CI:-77.9,-39.5 g/d;和-38.8 μmol/d;95%CI:-91.2,-10.7 μmol/d)。尽管干预组和对照组的 IHL 含量均降低(P<0.001 和 P=0.003),但干预组的 IHL 含量变化更为显著(差值:-0.7%点,95%CI:-2.0,-0.03%点)。两组间葡萄糖耐量和血清脂质的变化无显著差异。
与等热量对照组相比,单纯 6 周的果糖限制可使 IHL 含量有小但有统计学意义的降低。本试验在 clinicaltrials.gov 上注册,编号为 NCT03067428。